Posted by Michael Wonder on 23 Sep 2019
Xynomic Pharma receives fast track designation from the US FDA for abexinostat as fourth-line therapy treating follicular lymphoma
23 September 2019 - Xynomic Pharmaceuticals today announced that the U.S. FDA has granted fast track designation to Xynomic’s lead drug candidate abexinostat, for use as a single agent, as a fourth-line treatment of relapsed or refractory follicular lymphoma.
FDA has already granted fast track designation to abexinostat, in combination with pazopanib, as a first- or second-line treatment of renal cell carcinoma.
